Novel Insights into the Classification of Staphylococcal β-Lactamases in Relation to the Cefazolin Inoculum Effect
- 21 April 2020
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 64 (5)
- https://doi.org/10.1128/aac.02511-19
Abstract
Cefazolin has become a prominent therapy for methicillin-susceptible Staphylococcus aureus (MSSA) infections. However, an important concern is the cefazolin inoculum effect (CzIE), a phenomenon mediated by staphylococcal β-lactamases. Four variants of staphylococcal β-lactamases have been described based on serological methodologies and limited sequence information. Here, we sought to reassess the classification of staphylococcal β-lactamases and their correlation with the CzIE. We included a large collection of 690 contemporary bloodstream MSSA isolates recovered from Latin America, a region with a high prevalence of the CzIE. We determined cefazolin MICs at standard and high inoculums by broth microdilution. Whole-genome sequencing was performed to classify the β-lactamase in each isolate based on the predicted full sequence of BlaZ. We used the classical schemes for β-lactamase classification and compared it to BlaZ allotypes found in unique sequences using the genomic information. Phylogenetic analyses were performed based on the BlaZ and core-genome sequences. The overall prevalence of the CzIE was 40%. Among 641 genomes, type C was the most predominant β-lactamase (37%), followed by type A (33%). We found 29 allotypes and 43 different substitutions in BlaZ. A single allotype, designated BlaZ-2, showed a robust and statistically significant association with the CzIE. Two other allotypes (BlaZ-3 and BlaZ-5) were associated with a lack of the CzIE. Three amino acid substitutions (A9V, E112A, and G145E) showed statistically significant association with the CzIE (P = <0.01). CC30 was the predominant clone among isolates displaying the CzIE. Thus, we provide a novel approach to the classification of the staphylococcal β-lactamases with the potential to more accurately identify MSSA strains exhibiting the CzIE.Funding Information
- HHS | National Institutes of Health (R21 AI143229, R01 AI134637, K24 AI121296)
- Departamento Administrativo de Ciencia, Tecnologia e Innovacion (130880764150)
- Departamento Administrativo de Ciencia, Tecnologia e Innovacion (130880764152)
- Departamento Administrativo de Ciencia, Tecnologia e Innovacion (130874455850)
This publication has 49 references indexed in Scilit:
- SPAdes: A New Genome Assembly Algorithm and Its Applications to Single-Cell SequencingJournal of Computational Biology, 2012
- Predictors of Mortality in Staphylococcus aureus BacteremiaClinical Microbiology Reviews, 2012
- Is Cefazolin Inferior to Nafcillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia?Antimicrobial Agents and Chemotherapy, 2011
- Molecular differentiation of historic phage-type 80/81 and contemporary epidemic Staphylococcus aureusProceedings of the National Academy of Sciences of the United States of America, 2011
- Updated Functional Classification of β-LactamasesAntimicrobial Agents and Chemotherapy, 2010
- BLAST+: architecture and applicationsBMC Bioinformatics, 2009
- Inoculum Effect with Cefazolin among Clinical Isolates of Methicillin-Susceptible Staphylococcus aureus : Frequency and Possible Cause of Cefazolin Treatment FailureAntimicrobial Agents and Chemotherapy, 2009
- MUSCLE: multiple sequence alignment with high accuracy and high throughputNucleic Acids Research, 2004
- Change of a single amino acid in the leader peptide of a staphylococcal β-lactamase prevents the appearance of the enzyme in the mediumFEMS Microbiology Letters, 1990
- Clinical Experiences with Cefazolin and Other Cephalosporins in Bacterial EndocarditisThe Journal of Infectious Diseases, 1973